|
AML
|
AML (KMT2A/NPM1) | Newly diagnosed, intensive chemo eligible | Menin — 75276617ALE1001 | Phase 3 | Double‑blinded Bleximenib vs placebo with induction + consolidation
| Dr Chyn Chua |
|
AML
|
AML | RR AML or MCL | PEP07‑101 | Phase 1b | PEP07 Chk1 inhibitor monotherapy
| Prof Jake Shortt |
|
AML
|
AML | CR1/CR2 or oligoblastic relapse | Intercept — ALLG AMLM26 | Platform (Phase 2/3 domains) | MRD‑triggered multi‑arm precision platform
| Dr Chyn Chua |
|
AML
|
AML | CR1 post induction | CADENCE — ALLG AMLM22 | Phase 2/3 | Oral azacitidine vs oral azacitidine + Vididencil vaccine
| Prof Jake Shortt |
|
AML
|
AML | ND AML on Ven‑Aza | Adapt‑STOP — ALLG AMLM28 | Phase 2 | Randomised cessation of Ven‑Aza in MRD‑negative ND AML
| Dr Chyn Chua |
|
AML
|
AML/MDS/AML‑MDS | ND & RR | Apollo — AP30CP01 | Phase 1 | APL‑4098 ± azacitidine ± venetoclax
| Dr Chyn Chua |
|
AML
|
AML (NPM1/KMT2A) | RR | Menin — 75276617ALE1001 | Phase 1/2 | Bleximenib monotherapy
| A/Prof Pasquale Fedele |
|
MDS
|
MDS (IDH1+) | Newly diagnosed |PyramIDH — PyramIDH | Phase 3 | Ivosidenib vs azacitidine
| Dr Chyn Chua |
|
MDS/AML
|
AML/MDS | ND/RR | Apollo — AP30CP01 | Phase 1 | APL‑4098 ± azacitidine ± venetoclax
| Dr Chyn Chua |
|
MDS / MPN‑MDS
|
Transfusion‑dependent | TD | REDDS2 — REDDS2 | Randomised feasibility | Weekly vs usual transfusion schedule
| Dr Allison Mo |
|
CMML
|
CMML (TET2/RAS) | Treatment‑naive | PREACH‑M — PREACH‑M | Phase 2 | Mutation‑directed Aza + sodium ascorbate or Aza + lenzilumab
| Dr Ashvind Prabahran |
|
MPN
|
MF (JAK‑exposed) | RR | TP‑3654 — BBI‑TP3654‑102 | Phase 1/2 | TP‑3654 ± momelotinib (Arm 3 open)
| Dr Paul Yeh |
|
MPN
|
MF (suboptimal Ruxolitinib) | Ruxolitinib inadequate response | Navtemadlin — KRT‑232‑115 | Phase 3 | Navtemadlin + ruxolitinib vs placebo + ruxolitinib
| Dr Paul Yeh |
|
MPN
|
MF (JAK‑naive) | ND | Manifest‑3 — CDAK539A12303 | Phase 3 | Pelabresib + ruxolitinib vs placebo + ruxolitinib
| Dr Paul Yeh |
|
MPN
|
ET/PV/pre‑MF | Treatment‑naive | JBI‑802 — JBI‑802‑102 | Phase 1/2 | Dose‑finding JBI‑802 in thrombocytosis
| Dr Paul Yeh |
|
MPN
|
CML | Previously treated | CARDINAL — TERN‑701‑1012 | Phase 1/2 | Allosteric BCR::ABL1 inhibitor TERN‑701
| Prof Jake Shortt |
|
CLL/SLL
|
CLL | Treatment‑naive | BGB‑11417‑304 | Phase 3 | Sonrotoclax + zanubrutinib vs venetoclax + acalabrutinib
| Prof Stephen Opat |
|
CLL/SLL
|
CLL | RR | MOSUN — BO43243 | Phase 1 | Mosunetuzumab monotherapy or mosun + venetoclax
| Prof Stephen Opat |
|
CLL/SLL
|
CLL | RR | CELESTIAL‑RRCLL — BGB‑11417‑303 | Phase 3 | Sonrotoclax + anti‑CD20 vs venetoclax + rituximab
| Prof Stephen Opat |
|
CLL/SLL
|
CLL/SLL | RR | AETHER — ALLG CLL12 | Phase 1/2 | Venetoclax + epcoritamab (6 vs 12 cycles)
| Prof Stephen Opat |
|
CLL/SLL
|
CLL/SLL | RR/TN | BGB‑16673‑104 (Substudy 1b) | Phase 1b/2 | CDAC + sonrotoclax
| Dr Ross Salvaris |
|
CLL/SLL
|
CLL/SLL | Post‑Ven/Obi | MOONSHOT — ALLG CLL11 | Phase 2 | Epcoritamab monotherapy
| Prof Stephen Opat |
|
Indolent B-NHL
|
WM | RR | BGB‑16673‑104 (Substudy 1b) | Phase 1b/2 | CDAC + sonrotoclax
| Dr Ross Salvaris |
|
MCL
|
MCL | RR | PEP07‑101 | Phase 1b | Chk1 inhibitor monotherapy
| Prof Jake Shortt |
|
DLBCL
|
DLBCL | RR | NextGen — 95566692LYM1001 | Phase 1 | CD79b×CD20×CD3 trispecific antibody
| Dr Ross Salvaris |
|
DLBCL
|
DLBCL | MRD‑positive post‑1L | ALPHA‑3 — ALLO‑501A‑202 | Phase 2 | Cemacabtagene ansegedleucel CAR‑T
| Dr Danielle Oh |
|
B-cell NHL
|
DLBCL B‑cell lymphoma | RR | PALISADES‑1 — KT‑US‑499‑0150 | Phase 1/2 | KITE‑363 or KITE‑753 autologous anti‑CD19/CD20 CAR‑T therapies
| Dr Danielle Oh |
|
T‑cell NHL
|
Cytotoxic lymphoma / LGLL | RR | DR‑01 — DR‑01‑ONC‑001 | Phase 1/2 | DR‑01 monotherapy
| Prof Jake Shortt |
|
Myeloma
|
MM | Newly diagnosed | TRIlogy‑2 — 79635322MMY1002 | Phase 1b | JNJ‑79635322 + daratumumab ± IMiD
| A/Prof Michael Low |
|
Myeloma
|
MM | RR (≥3 lines) | TRIlogy‑4 — 79635322MMY3001 | Phase 3 | JNJ‑79635322 vs BCMA×CD3 bispecific
| Dr Jeremy Er |
|
Myeloma
|
MM | RR (t(11;14)) | BGB‑11417‑105 | Phase 1b/2 | Sonrotoclax + carfilzomib + dexamethasone
| A/Prof Michael Low |
|
Myeloma
|
MM | RR (Len‑exposed) | Quintessential — CA088‑1007 | Phase 3 | CAR‑T vs DPd/Kd
| Dr Danielle Oh |
|
Non‑Malignant
|
ITP / AIHA | RR | INCA00585 | Phase 2a | Tafasitamab monotherapy
| Dr Ashwini Bennett |
|
Non‑Malignant
|
Sickle Cell | ND/RR | Hibiscus‑2 | Phase 3 | Etavopivat vs placebo
| Dr Zane Kaplan |
|
Non‑Malignant
|
ITP | RR | TAK‑079‑3002 | Phase 3 | Mezagitamab vs placebo
| Dr Zane Kaplan |
|
Non‑Malignant
|
VTE | – | Butterfly | Phase 2 | LMWH via indwelling SC catheter
| Dr Emma Leitinger |
|
Non‑Malignant
|
Hypogammaglobulinemia | – | Rational‑PT | Adaptive platform | Adaptive IG replacement/cessation/dosing
| Dr Ross Salvaris |
|
Registry
|
Blood cancers | All AML/ALL/MPN/MM | National Blood Cancer Registry (NBCR) | Registry | National registry supporting AML platform trials and blood cancer outcomes
| Dr Chyn Chua |
|
Registry
|
Lymphoma / CLL | All B‑cell malignancies | LaRDR | Registry | Lymphoma and Related Diseases Registry
| Prof Stephen Opat |
|
Registry
|
Myeloma | All MM | Myeloma Registry | Registry | National myeloma outcomes registry
| |
|
Registry
|
TTP | TTP | TTP Registry | Registry | National registry for thrombotic thrombocytopenic purpura | |
